lead has been researched along with a-Synucleinopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Hamed, MR; Imam, RA | 1 |
| Avila, CL; Besnault, P; Brunel, JM; Chehín, R; Ferrié, L; Figadère, B; González-Lizárraga, F; Mella, RM; Michel, PP; Ploper, D; Raisman-Vozari, R; Rose, C; Salado, C; Seon-Méniel, B; Socías, SB; Tomas-Grau, R; Tourville, A; Villacé, P | 1 |
2 other study(ies) available for lead and a-Synucleinopathies
| Article | Year |
|---|---|
Vitamin D3 promotes oligodendrogenesis and modulates synucleinopathy in lead-induced nigral pars compacta neurotoxicity in rats.
Topics: alpha-Synuclein; Animals; Cholecalciferol; Lead; Pars Compacta; Rats; Rats, Wistar; Synucleinopathies | 2023 |
Neuroprotective Effects of a Novel Demeclocycline Derivative Lacking Antibiotic Activity: From a Hit to a Promising Lead Compound.
Topics: Anti-Bacterial Agents; Demeclocycline; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Lead; Neuroblastoma; Neuroprotective Agents; Synucleinopathies | 2022 |